Anaplastic lymphoma kinase (ALK) rearrangement has been observed in 3%–5% of non‐small cell lung cancers (NSCLCs).1, 2 ALK‐positive NSCLC is a distinct subgroup, and ALK tyrosine kinase inhibitors (TKIs) have been shown to prolong survival.3, 4, 5 Crizotinib, the first ALK inhibitor, showed superior outcomes compared to standard cytotoxic chemotherapy in advanced ALK‐positive NSCLC.3 Subsequently, ceritinib also showed its superiority to cytotoxic chemotherapy, and alectinib proved its efficacy compared to crizotinib.4, 5. Here, ALK is linked to non-small cell lung carcinoma.